<DOC>
	<DOCNO>NCT02444637</DOCNO>
	<brief_summary>Rivastigmine , acetylcholinesterase inhibitor approve FDA &amp; HSA , authorize use treatment mild moderate dementia Alzheimer 's type . In trial , investigator study effectiveness Rivastigmine subject AD cerebrovascular disease .</brief_summary>
	<brief_title>Open Label Trial Rivastigmine Patch Subjects With Mild Moderate Stage AD Having Coexisting svCVD</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Age 5085 year Diagnosis dementia Alzheimer 's type accord National Institute AgeingAlzheimer 's Association Criteriah MRI brain ( T2 FLAIR sequence ) perform within 12 month period time recruitment demonstrate presence WMH â‰¥2 Fazekas scale ( Score range 03 wherein score 1 indicates mild WMH , 2 indicates moderate WMH 3 indicate severe WMH ) .i Clinical Dementia Rating score 12j MiniMental State Examination ( MMSE ) score 1226 inclusivek English Mandarin speaking , literate participant Severe neurological , psychiatric systemic disease opinion clinician could interfere trial assessment The use investigational drug , new psychotropic dopaminergic agent , cholinesterase inhibitor anticholinergic agent 4 week prior recruitment Known skin allergy previous allergic reaction Rivastigmine patch</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>